Dextromethorphan/Quinidine for the Treatment of Pseudobulbar Affect
Data Sources: A literature search of MEDLINE/PubMed (January 1966-June 2013) was conducted using search terms pseudobulbar affect, pathological laughing and/or crying, emotional lability, dextromethorphan, and quinidine.
Study Selection and Data Extraction: English language clinical trials and case reports evaluating the safety and efficacy of DM/Q in PBA were included for review. Bibliographies of all relevant articles were reviewed for additional citations.
Data Synthesis: PBA, a poorly understood disorder, is characterized by involuntary crying and/or laughing. In the past, antidepressants and antiepileptics have been used off-label with mixed results. Four clinical trials have evaluated the use of DM/Q for the treatment of PBA. Although the therapeutic outcomes with DM/Q have been positive, interpretation of the published evidence is limited by small sample size and short treatment duration.
Conclusions: Based on the data available, DM/Q may be a viable, short-term treatment alternative for PBA. Long-term safety and efficacy data are lacking.
Keywords: AD = Alzheimer's disease; AE = Adverse effect; ALS = Amyotrophic lateral sclerosis; Antidepressants; CNS-LS = Center for Neurologic Study Lability Scale; CYP = Cytochrome; DM/Q = Dextromethorphan/quinidine; Dextromethorphan; Emotional lability; FDA = Food and Drug Administration; ICD = International Classification of Diseases; MS = Multiple sclerosis; NMDA = N-methyld-aspartate; PBA = Pseudobulbar affect; PD = Parkinson's disease; PLACS = Pathological Laughing and Crying Scale; PLC = Pathological laughing or crying; Pathological laughing and crying; Pseudobulbar affect; Quinidine; SSRIs = Selective serotonin reuptake inhibitors; TBI = Traumatic brain injury; TCAs = Tricyclic antidepressants
Document Type: Research Article
Publication date: 01 April 2014
- The Consultant Pharmacist® is the official peer-reviewed journal of the American Society of Consultant Pharmacists. It is dedicated exclusively to the medication needs of the elderly in all settings, including adult day care, ambulatory care, assisted living, community, hospice, and nursing facilities. This award-winning journal is a member benefit of ASCP. Individuals who are not members and wish to receive The Consultant Pharmacist® will want to consider joining ASCP.
- Information for Authors
- Submit a Paper
- Subscribe to this Title
- Membership Information
- Information for Advertisers
- ">
- Ingenta Connect is not responsible for the content or availability of external websites
Receive new issue alert- Access Key
- Free content
- Partial Free content
- New content
- Open access content
- Partial Open access content
- Subscribed content
- Partial Subscribed content
- Free trial content